Gorin Sherri Sheinfeld, Heck Julia E, Albert Steven, Hershman Dawn
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA.
J Am Geriatr Soc. 2005 Nov;53(11):1897-904. doi: 10.1111/j.1532-5415.2005.00467.x.
To report use of breast cancer treatment (surgery, radiation, and chemotherapy) by patients with Alzheimer's disease (AD).
Retrospective cohort study.
Surveillance, Epidemiology, and End Results (SEER) is a population-based cancer registry covering 14% of the U.S. population.
Fifty thousand four hundred sixty breast cancer patients aged 65 and older, of whom 1,935 (3.8%) had a diagnosis of AD before or up to 6 months after cancer diagnosis.
Diagnosis of AD was taken from International Classification of Diseases, Ninth Revision, diagnostic codes accompanying Medicare billing claims between 1992 and 1999. The SEER program reported surgery and radiation. Chemotherapy was taken from Medicare billing records.
Subjects with AD were diagnosed with breast cancer at later stages, when tumors were larger and the likelihood of lymph node involvement had increased. Patients with AD had a lower likelihood of surgery (odds ratio (OR)=0.60, 95% confidence interval (CI)=0.46-0.81), radiation (OR=0.31, 95% CI=0.23-0.41), and chemotherapy (OR=0.44, 95% CI=0.34-0.58) than those without AD.
Overall, AD patients receive less treatment for breast cancer than do comparable female Medicare beneficiaries. Chemotherapy and radiation are administered less frequently to women with AD than to other comparable patients. It is unclear whether suboptimal medical care has an effect on their survival. Further research on the effect of screening and treatment decision-making for these patients is warranted.
报告阿尔茨海默病(AD)患者的乳腺癌治疗(手术、放疗和化疗)情况。
回顾性队列研究。
监测、流行病学和最终结果(SEER)是一个基于人群的癌症登记系统,覆盖美国14%的人口。
50460名65岁及以上的乳腺癌患者,其中1935名(3.8%)在癌症诊断前或诊断后6个月内被诊断为AD。
AD的诊断依据国际疾病分类第九版,取自1992年至1999年医疗保险计费索赔所附的诊断代码。SEER项目报告了手术和放疗情况。化疗情况取自医疗保险计费记录。
AD患者在癌症晚期被诊断出患有乳腺癌,此时肿瘤更大,淋巴结受累的可能性增加。与没有AD的患者相比,AD患者接受手术(比值比(OR)=0.60,95%置信区间(CI)=0.46 - 0.81)、放疗(OR = 0.31,95% CI = 0.23 - 0.41)和化疗(OR = 0.44,95% CI = 0.34 - 0.58)的可能性更低。
总体而言,AD患者接受的乳腺癌治疗比类似的女性医疗保险受益人少。与其他类似患者相比,AD女性接受化疗和放疗的频率更低。尚不清楚医疗服务欠佳是否会影响她们的生存。有必要对这些患者的筛查和治疗决策的影响进行进一步研究。